Abdullahi Bello Umar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abdullahi Bello Umar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Adamu Uzairu
Department of Chemistry, Faculty of Physical Sciences, Ahmad Bello University, Zaria, Kaduna State, Nigeria
2 shared publications- Adamu Uzairu
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria, Nigeria
2 shared publications - Gideon Adamu Shallangwa
Ahmadu Bello University
2 shared publications - Abdullahi Muhammad Ayuba
Department of Pure and Industrial Chemistry, Bayero University Kano, Kano, Nigeria
1 shared publication - Aliyu Habib
Department of Biological Sciences, Ummaru Musa Yar′ Adua University, Katsina, Nigeria
1 shared publication - Aqel Albutti
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 7 October 2024
- Published by Springer Nature in Discover Chemistry
- Vol. 1 (1) , 1-26
Cheminformatic evaluation of the multi-protein binding potential of some diselenide derivatives: A plausible drug discovery approach for leishmaniasis
- 7 October 2024
- Published by Springer Nature in Discover Chemistry
- Vol. 1 (1) , 1-26
Open AccessCheminformatic evaluation of the multi-protein binding potential of some diselenide derivatives: A plausible drug discovery approach for leishmaniasis
- 4 May 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (6) , 3027-3038
Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600E-BRAF Inhibitors Through Computational Approaches
- 4 May 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (6) , 3027-3038
Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600E-BRAF Inhibitors Through Computational Approaches
- Open Access
- 2 March 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (5) , 1000-1010
New flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties
- 2 March 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (5) , 1000-1010
Open AccessNew flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties
- Open Access
- 16 October 2020
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 44 (1) , 1-11
Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties
Background: V600E-BRAF protein target has much potential for scientific research as therapeutic target due to its involvement in human melanoma cancer. In the current research, molecular docking investigation was conducted on some flavone-based arylamides as anticancer drug candidates via V600E-BRAF inhibition with the help of docking software Molegro Virtual Docker. Based on the predicted results, existing structures were modified and screened for pharmacokinetics ADMET properties. Results: The docking result demonstrates that compound 28 best inhibits V600E-BRAF when compared with other compounds within the dataset. This compound was used as a template in designing novel anticancer compounds by attaching some favorable substituents. The docking results of the designed compounds revealed a good MolDock score (< − 90), which showed that all the compounds can efficiently bind with the active sites of the target, out of which two analogous (N1 and N3) were considered optimal that outperformed vemurafenib, the FDA-approved V600E-BRAF inhibitor. Furthermore, these compounds passed the drug-likeness criteria (Lipinski’s rule) successfully and were found to be orally bioavailable. Also, the designed compounds were found to have good pharmacokinetics absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Conclusion: Thus, this study identified compounds (N1 and N3) as the best hits against V600E-BRAF kinase with enhanced pharmacological properties and recommends their synthesis, in vivo and ex vivo evaluation to validate our hypothesis.
- 16 October 2020
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 44 (1) , 1-11
Open AccessDocking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties
Background: V600E-BRAF protein target has much potential for scientific research as therapeutic target due to its involvement in human melanoma cancer. In the current research, molecular docking investigation was conducted on some flavone-based arylamides as anticancer drug candidates via V600E-BRAF inhibition with the help of docking software Molegro Virtual Docker. Based on the predicted results, existing structures were modified and screened for pharmacokinetics ADMET properties. Results: The docking result demonstrates that compound 28 best inhibits V600E-BRAF when compared with other compounds within the dataset. This compound was used as a template in designing novel anticancer compounds by attaching some favorable substituents. The docking results of the designed compounds revealed a good MolDock score (< − 90), which showed that all the compounds can efficiently bind with the active sites of the target, out of which two analogous (N1 and N3) were considered optimal that outperformed vemurafenib, the FDA-approved V600E-BRAF inhibitor. Furthermore, these compounds passed the drug-likeness criteria (Lipinski’s rule) successfully and were found to be orally bioavailable. Also, the designed compounds were found to have good pharmacokinetics absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Conclusion: Thus, this study identified compounds (N1 and N3) as the best hits against V600E-BRAF kinase with enhanced pharmacological properties and recommends their synthesis, in vivo and ex vivo evaluation to validate our hypothesis.
- 18 September 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 3 (4) , 1009-1022
QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line
- 18 September 2020
- Published by Springer Nature in Chemistry Africa
- Vol. 3 (4) , 1009-1022
QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line